Frequently Asked Questions
The market is segmented based on Europe Rapid Diagnostic Test (RDT) Market Segmentation, By Product Type (Consumables and Kits, Instruments, and Others), Mode (Professional and Over-The-Counter [OTC]), Technology (PCR-Based, Flow-Through Assays, Lateral Flow Immunochromatographic Assays, Agglutination Assay, Microfluidics, Substrate Technology, and Others), Modality (Laboratory Based Test and Non-Laboratory Based Test), Age Group (Adult and Pediatric), Test Type (Determining Confirmation, Serological Testing and Viral Sequencing), Approach (In-Vitro Diagnostic and Molecular Diagnostic), Specimen (Swab, Blood, Urine, Saliva, Sputum, and Others), Application (Infectious Disease Testing, Glucose Monitoring, Cardiology Testing, Oncology Testing, Cardiometabolic Testing, Drugs-of-Abuse Testing, Pregnancy & Fertility Testing, Toxicology Testing, and Others), End User (Hospital & Clinic, Diagnostic Laboratory, Home Care Setting, Research and Academic Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends and Forecast to 2032
.
The Europe Rapid Diagnostic Tests Rdt Market size was valued at USD 13.03 USD Billion in 2024.
The Europe Rapid Diagnostic Tests Rdt Market is projected to grow at a CAGR of 8.2% during the forecast period of 2025 to 2032.
The major players operating in the market include Abbott, Danaher, Cellex, Fujirebio, AdvaCare Pharma.
The market report covers data from the Europe.